Senseonics (SENS) Posts Earnings Results, Misses Estimates By $0.05 EPS

Senseonics (NYSEAMERICAN:SENS) announced its quarterly earnings results on Thursday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.05), Fidelity Earnings reports. The firm had revenue of $3.42 million during the quarter, compared to analyst estimates of $4.05 million.

Shares of NYSEAMERICAN:SENS traded down $0.22 on Friday, reaching $2.14. The company had a trading volume of 1,631,581 shares, compared to its average volume of 1,702,662. Senseonics has a 52-week low of $1.93 and a 52-week high of $5.29.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Senseonics by 6.1% in the 4th quarter. BlackRock Inc. now owns 6,142,950 shares of the company’s stock worth $15,910,000 after purchasing an additional 352,590 shares in the last quarter. Vanguard Group Inc boosted its position in shares of Senseonics by 8.7% in the 3rd quarter. Vanguard Group Inc now owns 4,779,370 shares of the company’s stock worth $22,797,000 after purchasing an additional 382,058 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Senseonics by 8.7% in the 3rd quarter. Vanguard Group Inc. now owns 4,779,370 shares of the company’s stock worth $22,797,000 after purchasing an additional 382,058 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Senseonics by 19.9% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,696,533 shares of the company’s stock worth $9,574,000 after purchasing an additional 613,995 shares in the last quarter. Finally, City Financial Investment Co Ltd boosted its position in shares of Senseonics by 38.2% in the 4th quarter. City Financial Investment Co Ltd now owns 1,450,000 shares of the company’s stock worth $3,756,000 after purchasing an additional 401,000 shares in the last quarter. 30.66% of the stock is owned by hedge funds and other institutional investors.



A number of research analysts have recently issued reports on the company. Zacks Investment Research downgraded Senseonics from a “hold” rating to a “sell” rating in a report on Saturday. Piper Jaffray Companies assumed coverage on Senseonics in a report on Tuesday, January 29th. They issued a “neutral” rating on the stock. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $6.00.

ILLEGAL ACTIVITY WARNING: “Senseonics (SENS) Posts Earnings Results, Misses Estimates By $0.05 EPS” was originally reported by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://dakotafinancialnews.com/2019/05/11/senseonics-sens-posts-earnings-results-misses-estimates-by-0-05-eps.html.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Featured Story: Overbought

Earnings History for Senseonics (NYSEAMERICAN:SENS)

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.